ESC: MyoKardia’s mavacamten boosts heart function in phase 3, teeing up 2021 filing
Earlier this year, MyoKardia presented preliminary data showing its long-awaited targeted heart therapy mavacamten could move the needle on certain cardiac protein biomarkers linked to signs of heart stress and injury.